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Amyotrophic lateral sclerosis is a neurodegenerative disease predominantly
affecting upper and lower motor neurons, resulting in progressive paralysis and
death from respiratory failure within 2 to 3 years. The peak age of onset is 55 to
70 years, with a male predominance. The causes of amyotrophic lateral
sclerosis are only partly known, but they include some environmental risk
factors as well as several genes that have been identified as harbouring
disease-associated variation. Here we review the nature, epidemiology, genetic
associations, and environmental exposures associated with amyotrophic lateral
sclerosis.
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Introduction
Amyotrophic lateral sclerosis (ALS) is an incurable condition, 
characterised by progressive degeneration of upper and lower 
motor neurons, resulting in paralysis and death from respiratory 
failure in a median of 2–3 years1. Despite the poor prognosis, there 
is considerable variation in the survival rate, and up to 10% of 
people with ALS live for more than 8 years from first symptoms2. 
Understanding what causes ALS or influences survival is crucial for 
the development of effective treatments.
The causes of ALS are largely unknown. Significant advances 
have been made in understanding the genetic and environmental 
components of the disease. In this report, we will explore what 
is known about why some people develop ALS and how the risk 
factors work together to cause the disease.
Epidemiological studies of ALS
The incidence of ALS is about 2 per 100,000 person-years, and 
the prevalence is about 5 per 100,000 persons3. Because of the low 
prevalence, the average primary care physician will see 1 person 
in their lifetime, a typical UK neurologist will diagnose about 
2 people a year, while a tertiary referral centre will see more 
than 100 people. Despite the low incidence, however, ALS is not 
particularly infrequent. The lifetime risk is about 1 in 300 by the 
age of 85, with the risk increasing steadily, at least until about the 
eighth decade of life4,5. This is very similar to the risk for multiple 
sclerosis in the UK6.
Tertiary referral centres see sufficient numbers of people that 
research studies will have adequate power for statistical analy-
sis. However, there is a significant diagnostic delay in ALS, typi-
cally about a year, which seems to be independent of healthcare 
system and is probably related to low recognition by primary care 
physicians7. As a result, those attending specialist centres tend to 
be those with a better prognosis, who are younger, and who are 
more motivated8,9. In contrast, population-based registers capture 
all cases in a defined catchment population, regardless of attend-
ance at a specialist clinic. Such registers have provided valuable 
insights into the epidemiology of ALS and offer an unbiased view 
of the condition10.
ALS can affect people at any age. The mean age of onset is 56 in 
clinic registers but 70 in population-based registers. In clinic reg-
isters, ALS is more frequent in men, with a male:female ratio of 
about 3:2, and the ratio becomes more equal with increasing age. In 
population registers, although the male preponderance is still seen, 
the ratio may be closer to 1:1, an effect that can be attributed to the 
greater capture of older people with ALS3.
What is ALS?
ALS presents in many different ways (Table 1), and it has been 
recognised for many years that the different clinical presentations 
correspond with differences in survival11,12. Bulbar palsy, in which 
dysarthria followed by swallowing difficulty is the main presenta-
tion, is associated with the worst prognosis, and flail arm or flail leg 
Table 1. Clinical presentations of amyotrophic lateral sclerosis.
Classifying 
feature
Name of phenotype Description
Motor neuron 
involvement
Amyotrophic lateral 
sclerosis (ALS)
Mixture of upper and lower motor neuron signs on clinical examination. 
Degree of certainty of diagnosis based on El Escorial criteria. May 
involve up to all regions.
Primary lateral sclerosis 
or upper motor neuron 
predominant ALS
Clinical signs limited to upper motor neuron features. Generally slowly 
progressive but involving up to all regions. This phenotype is usually 
confirmed if there have been no lower motor neuron signs after 4 years.
Progressive muscular 
atrophy or lower motor 
neuron predominant ALS
Clinical signs limited to lower motor neuron features. Slightly slower 
progression but can involve all regions. This phenotype is usually 
confirmed if there have been no upper motor neuron signs after 4 years.
Site of onset Bulbar onset Site of onset may be included in the description of ALS, as different 
disease onset patterns have different rates of progression. The two 
categories are bulbar and spinal.Spinal onset
Disease 
focality
Progressive bulbar palsy Condition involving the bulbar region and predominantly lower motor 
neurons. May progress to other regions.
Pseudobulbar palsy Condition involving the bulbar region and predominantly upper motor 
neurons. May progress to other regions.
Flail arm Predominantly lower motor neuron proximal symmetrical involvement in 
the upper limbs. Some upper motor neuron signs may be seen in the 
lower limbs.
Flail leg Lower motor neuron distal symmetrical involvement restricted to the lower 
limbs. May affect one side only.
Cognitive 
involvement
ALS with cognitive 
impairment
ALS with some cognitive involvement below the threshold criteria for 
frontotemporal dementia.
ALS with frontotemporal 
dementia (ALS-FTD)
ALS with frank frontotemporal dementia.
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syndrome, in which there is symmetrical, predominantly flaccid 
weakness of the limbs, is associated with the best prognosis13. Per-
haps surprisingly, statistical methods such as latent class cluster 
analysis can analyse the same data and identify different clinical 
subtypes that predict prognosis with far more discrimination than 
can neurologist classifications13. Most cases of ALS are focal in 
onset and relentlessly progressive, often to contiguous regions, 
although there are some exceptions14. The spread could be the 
result of a “prion-like” spread of toxic proteins through phagocy-
tosis (consumption of cells by other cells) or possibly through a 
time-to-failure model15–17. Lower motor neuron failure is the main 
cause of weakness in ALS and can be measured non-invasively to 
provide data to assess cellular patterns of spread18. Understanding 
the mechanisms of spread will aid the development of novel 
therapeutics and may aid models of prognosis.
The diagnosis of ALS is clinical, with the support of electrophysi-
ological studies and the exclusion of mimics. In some cases, early 
diagnosis can be challenging, particularly if weakness is confined 
to one region for some time or is confined to a subset of motor neu-
rons (upper only or lower only). A sensitive set of electrodiagnostic 
criteria, the Awaji criteria, can be particularly useful in the early 
diagnosis of people with bulbar onset disease, which is important 
because of the need for sooner gastrostomy when swallowing is 
affected early19–22.
ALS is classified for research purposes by the El Escorial crite-
ria and their revisions, which improve homogeneity in recruitment 
for clinical trials and other clinical studies23–26. ALS progression 
is measured functionally using the ALS Functional Rating Scale 
– Revised, which uses 12 questions scored between 0 (no function) 
and 4 (full function) to generate a summary score27. The scale is 
widely used but has some limitations, since the subscores correlate 
more accurately with progression in different clinical subtypes28.
Disease staging allows a simple description of the extent of physi-
cal or functional involvement in an affected person and guides 
management. Such systems have been in widespread use in cancer 
for years. In ALS, two recent staging systems have been proposed: 
King’s clinical staging and Milano-Torino staging (MiToS)29,30. The 
King’s system is similar to cancer staging in that the clinical spread 
of disease is used to infer the extent of disease progression. Spread 
is defined as involvement producing signs or symptoms in the 
El Escorial domains (1 domain is stage 1, 2 domains is stage 2, 
and 3 domains is stage 3), with respiratory or nutritional failure 
characterising stage 4. The ALS functional rating scale can be used 
to estimate the King’s stage with 92% correlation31. MiToS uses the 
ALS functional rating scale subscores to define functional stage29. 
Each system has benefits in describing ALS stage succinctly. The 
two disease staging systems are complementary32. King’s staging 
summarises the clinical or anatomical spread of disease. Mapping 
disease progression to clinical stage rather than survival could be 
used as a secondary endpoint in clinical trials, which would shorten 
trial durations and provide meaningful information on which stage 
of the disease is prolonged by an effective therapy33. MiToS sum-
marises the functional burden of disease. It would therefore be use-
ful in showing a functional benefit in clinical trials. Comparison of 
the systems shows that functional stage lags behind clinical stage, 
reflecting the functional reserve available in an affected limb, and it 
has been proposed that a combined stage is used, as is standard in 
cancer, along the lines of K3M2, which would mean King’s stage 3, 
MiToS stage 232,34 (Figure 1).
It is now recognised that ALS involves non-motor systems35. 
Between 30 and 50% of people have cognitive impairment detect-
able on formal testing, resulting from involvement of the fronto-
temporal circuits36,37. Frank frontotemporal dementia occurs in 
about 5%, and in some families, people may have ALS, frontotem-
poral dementia, or both36,38,39. The clinical impact of frontotempo-
ral impairment in ALS is now more easily recognised because of 
recent advances in the tools available to detect it, such as the 
Edinburgh cognitive assessment score (ECAS)40,41. Other neu-
rodegenerative diseases have also been linked to ALS, including 
spinocerebellar ataxia, in which case studies have reported the co-
occurrence of ALS and cerebellar degeneration42. Schizophrenia 
may be more frequent in families with ALS, and there may also 
be an increased frequency of multiple sclerosis43,44. In many of 
these cases, genetic factors are responsible for some of the risk. 
For example, pathological expansion of a repeat sequence in the 
C9orf72 gene is associated with ALS, frontotemporal dementia, or 
both, and the same mutation may increase the risk of schizophre-
nia, Parkinson’s disease, and multiple sclerosis45. Expansion of a 
repeat sequence in the ATXN2 gene is associated with ALS or, if 
more than 30 repeats are involved, with spinocerebellar ataxia46. 
Autonomic, skin, and eye movement changes are also seen. Thus, 
ALS is a neurodegenerative disease in which the brunt falls on the 
motor system, but, as for many other neurodegenerations, the clini-
cal syndrome is also dispersed through other anatomical and physi-
ological systems.
Understanding prognostic factors in ALS
Respiratory impairment is usually an end-stage event in ALS. 
Despite this, because respiratory function is difficult to measure 
reliably with non-invasive methods, measurement of respiratory 
function is generally used as a guide to the use of respiratory sup-
port rather than prognostication47. There have been many attempts 
at prognostic modelling, using either clinical features alone or 
biological markers such as albumin, creatinine, or neurofilament 
levels48,49. Most studies find that longer survival is associated with 
younger age at symptom onset, presentation with limb dysfunc-
tion rather than swallowing or speech disturbance, and specific 
forms of ALS such as symmetrical patterns (e.g. flail arm syn-
drome) or upper motor neuron predominant forms50. Conversely, 
cognitive impairment comprising executive dysfunction, rapid 
weight loss, and respiratory involvement at first examina-
tion, although not necessarily respiratory onset, predict a poor 
prognosis51–58. The best predictor of slow progression, however, 
appears to be a long interval between symptom onset and diagno-
sis, probably because this reflects the rate of disease progression 
overall59. Genetic variations have been associated with survival 
duration, with the best studied being variation in the UNC13A 
gene60,61. Variation in the CAMTA1 gene has also been associ-
ated with survival62. Furthermore, some risk genes harbour vari-
ants that are themselves predictors of prognosis. For example, the 
p.Asp91Ala variation of the SOD1 gene is associated with very 
slow progression63,64, while the p.Ala5Val variant is associated 
with aggressive disease65. Statistical models can be used to provide 
clinically useful information for patients, the strongest message 
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Figure 1. The time course of amyotrophic lateral sclerosis (ALS). Time is represented along the x-axis; physical health and molecular 
damage are represented along the y-axis. With time, molecular damage increases in a step-wise way until it reaches a threshold, at which point 
physical health declines, representing disease onset. People with a family history of ALS may have a large genetic predisposition to ALS and 
so need fewer steps to reach the level of molecular damage that causes disease, corresponding to a younger age of onset. Lack of exposure 
to sufficient risk factors means that the disease does not manifest, even if a genetic cause is present, explaining reduced penetrance. There 
is not a 1:1 mapping of risk factors and steps, as the steps represent molecular hits that lead to cellular damage rather than actual exposures. 
Once physical symptoms have started, progression shows a log-linear decline until the onset of respiratory symptoms, where decline is 
exponential. Clinical and functional involvement can be measured by the King’s clinical staging and Milano-Torino staging (MiToS) systems. 
A dotted line represents the hypothetical trajectory in an unaffected individual. Black arrows represent genetic and environmental risk factors. 
Numbers indicate remaining molecular hits until disease onset.
being that survival is extremely unreliably predicted in individuals, 
even though patterns can be seen in the data54,57,66–68.
Genetics and ALS
There are now more than 25 genes in which an association with 
ALS has been replicated, with the rate of gene discovery doubling 
every 4 years (http://alsod.iop.kcl.ac.uk)69. In up to 10% of peo-
ple, there is a family history of ALS in a first-degree relative, but 
detailed genealogical studies extending to more distant relatives 
and including related diagnoses suggest that more than 20% have 
a relevant family history. The genes responsible for familial ALS 
have now been identified for about 70% of all cases, but there is 
a significant genetic component, even in those without a family 
history. Twin studies suggest the heritability is about 60%, and 
nearly every familial ALS gene has also been implicated in appar-
ently sporadic ALS70,71. Furthermore, statistical analysis shows that 
the distinction between familial and sporadic ALS is not clear-
cut, and large-scale genome-wide association studies (GWAS) 
show that the genetic architecture of sporadic ALS is one in which 
rare variation, more usually associated with familial disease, is 
disproportionately important72,73.
The most recent GWAS of ALS identified four new associations, 
three of which were successfully replicated73. An interesting 
feature of the study was that even though this was a study of 
people with apparently sporadic ALS, there were associations in 
genes previously identified from family-based studies – C9orf72, 
TBK1, and NEK1 – further supporting the notion that familial and 
sporadic ALS are not mutually exclusive categories but rather a 
spectrum74–76. These three genes all harbour variants that are mod-
erately penetrant. In other words, carrying a disease-associated 
variant does not mean ALS will inevitably follow. Current think-
ing is that common diseases are the consequence of the additive 
effects of small increases in risk from multiple common variations 
(polygenic), and rare diseases are the consequence of single 
gene variants that are themselves rare but have a large effect on 
the probability of disease (monogenic). For example, height and 
schizophrenia are polygenic traits, while Huntington’s dis-
ease and Kennedy’s disease are monogenic diseases. ALS sits 
somewhere between these two extremes, with a lifetime prevalence 
that is far greater than is typical for a monogenic disease but far less 
than a common disease, and it is perhaps, therefore, to be 
expected that its genetic architecture also seems to sit somewhere 
between polygenic effects and monogenic high-penetrance 
disease.
There are three genes that have had a major impact on our under-
standing of ALS. ALS-linked dominant mutations in the superoxide 
dismutase gene SOD1 were first identified in 1993, and since then 
mutations have been found in every exon of the gene77. The SOD1 
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protein is a free radical scavenger, and loss of function, increas-
ing free radical damage in cells, is a logical hypothesis to consider. 
However, several well-characterised SOD1 variants do not lead to 
a reduction in dismutase activity, and the evidence instead supports 
a toxic gain of function78. Transgenic SOD1 mice develop a motor 
neuron degeneration and have been used to model the disease for 
treatment development79. The second important ALS gene is TAR-
DBP, which codes for TDP-43, a protein regulating RNA expres-
sion and the major component of intracellular inclusions in ALS. 
The discovery of ALS-linked mutations in this gene was the first 
of many showing RNA processing defects to be important in ALS 
pathogenesis and, importantly, showed that the TDP-43 inclusions 
were not simply a passive marker of neuronal death but a crucial 
part of the disease pathway80–82. The third important genetic finding 
in ALS was of linkage83,84 and then association85–87 of a locus on 
chromosome 9, which led researchers to the identification of a 
massive expansion of a hexanucleotide repeat in intron 1 of the 
C9orf72 gene88,89. This is the most frequent cause of ALS, being 
responsible for about 30% of familial and up to 10% of sporadic 
cases.
The focus of genetic research in ALS in the immediate future is 
therefore on rare variation. This is best discovered through high-
throughput sequencing, and this technique has already identified 
several familial ALS genes. The major challenge facing researchers 
is how to interpret the findings, since the identification of a rare 
variant in an ALS gene is not in itself strong evidence of relevance 
in that individual, and over-representation of rare variation in cases 
over controls in a particular gene does not provide sufficient infor-
mation for genetic counselling on a specific variant90. The amount of 
heritability explained by genetic information captured on genome-
wide microarrays is about 12%, implying that the remainder is 
in rare variants and other types of genetic variation such as copy 
number variation, microsatellite repeats, post-transcriptional RNA 
editing, and epigenetic changes91. These are likely to be the next 
targets of ALS genetics research and are reliant on international 
research consortia. Project MinE is one such global collaboration 
that aims to analyse DNA from at least 15,000 people with ALS and 
7,500 controls (https://www.projectmine.com/).
Environmental risk factors
In contrast to genetics, environmental risk factors for ALS have been 
more difficult to identify. Such studies are expensive to perform but 
difficult to fund and are heavily reliant on recall92. As a result, they 
are susceptible to bias. Furthermore, unlike genome-wide analyses, 
in which a hypothesis-generating approach can be taken, it is not 
straightforward to assay all possible environmental factors, and so a 
selected subset of assumed risk factors is tested. Smoking has been 
associated with increased risk of ALS in some studies and may hold 
a higher risk in some subgroups93. Occupation, particularly military 
service with deployment, has been associated with risk of ALS, but 
the evidence mainly comes from the US, where there are large mili-
tary datasets94. Physical activity is another widely studied risk fac-
tor, partly because of a number of high-profile sports players who 
have had ALS and because of people with ALS having a low BMI 
on presentation and higher levels of leisure sports participation95. 
It is not clear whether having higher levels of physical activity 
raises the risk of ALS and, if it does, whether it is the activity itself 
or being genetically predisposed to high sporting prowess that is 
the mechanism96. Similarly, electric shock is not a risk factor in 
some analyses but is in others97,98. There is mixed evidence for the 
involvement of chemicals, such as heavy metals, ambient aromatic 
hydrocarbons, pesticides, and cyanotoxins99–103. Trauma, including 
head injury, also appears to be a risk factor in meta-analysis104.
Inflammation and ALS
Evidence of an immuno-inflammatory component in ALS patho-
genesis is compelling105,106. A pathological hallmark of the neu-
roinflammation is prominent microglia activation at involved sites. 
T-regulatory lymphocytes (Tregs) are important immunomodula-
tory cells that regulate the balance between activation and suppression 
of the immune response and control the microglia in the central 
nervous system: specifically, pushing them towards a state in which 
remodeling and repair activities are activated. Defects in Treg 
levels or function have been found in ALS patients, becoming 
more frequent as the disease progresses. Treg levels are inversely 
correlated with disease severity, so that lower levels are seen in more 
severe disease, and survival is worse in those with Treg defects105–109. 
Studies are now underway to explore immune therapies that might 
improve Treg function and therefore improve survival.
Retroviruses and ALS
Poliovirus and other enteroviruses can cause a post-infectious mye-
litis with subsequent paralysis, and HIV infection can result in an 
ALS-like syndrome. Studies of serum and cerebrospinal fluid from 
ALS patients suggested that an activated endogenous retrovirus 
was associated with ALS110. Recently, the sequence has been identi-
fied as possibly HERV-K, an endogenous retrovirus that exists as 
an open reading frame in the human genome111. In mice, the env 
protein component of HERV-K is toxic to motor neurons. There is 
no evidence that HERV-K is causative of the disease in humans, but 
studies are now underway to explore if antiretrovirals might slow 
progression and improve survival in ALS.
Conclusion
The apparently homogeneous phenotype of predominantly motor 
degeneration that is ALS can result from many different causes: 
genetic, epigenetic, environmental, and internal. Thus, many dif-
ferent pathways converge on the final outcome of upper and 
lower motor neuron death. Careful analysis of incidence data in 
European population registers shows that, on average, each pathway 
comprises six molecular steps112 (see Figure 1). The model explains 
many otherwise enigmatic features of ALS, such as the increasing 
risk with age, genetic pleiotropy (the same gene variation can result 
in different diseases), age-dependent penetrance of disease genes, 
the difficulty in identifying a single environmental cause, the obser-
vation that ALS appears to start in one region and spread, and that it 
is specific to motor neurons but can affect other cell types. The next 
challenge is to understand the extent to which the pathways overlap 
and therefore might be amenable to a common treatment strategy. 
Although ALS remains a uniformly fatal diagnosis, accelerating 
advances in our understanding bring the hope that an effective treat-
ment can be found for this devastating disease.
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